DHC is a real estate investment trust focused on owning high-quality healthcare properties located throughout the United States. DHC seeks diversification across the health services spectrum by care delivery and practice type, by scientific research disciplines and by property type and location. As of September 30, 2024, DHC’s approximately $7.2 billion portfolio included 368 properties in 36 states and Washington, D.C., occupied by approximately 500 tenants, and totaling approximately 8.2 million square feet of medical office and life science properties and more than 27,000 senior living units. DHC is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with nearly $41 billion in assets under management as of September 30, 2024 and more than 35 years of institutional experience in buying, selling, financing and operating commercial real estate. DHC is headquartered in Newton, MA.
Strategic Outlook | Discover DHC's efforts to optimize its portfolio through asset sales and operational improvements, balancing near-term financial pressures with long-term growth prospects. |
Market Positioning | Learn how DHC's market valuation reflects both its challenges and potential, with a Core FFO multiple of 27x against a peer average of 23x, and a cautious analyst outlook. |
Financial Challenges | Delve into DHC's financial landscape, marked by revised NOI guidance, negative EPS, and a complex debt structure, as it strives for operational efficiency. |
Portfolio Dynamics | Explore DHC's diverse healthcare real estate portfolio, featuring senior living communities and medical offices, as it navigates mixed segment performance and strategic dispositions. |
Metrics to compare | DHC | Sector Sector - Average of metrics from a broad group of related Real Estate sector companies | Relationship RelationshipDHCPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.6x | 32.4x | 8.3x | |
PEG Ratio | 0.06 | −0.05 | 0.01 | |
Price / Book | 0.3x | 1.9x | 0.9x | |
Price / LTM Sales | 0.4x | 6.7x | 3.7x | |
Upside (Analyst Target) | −18.7% | 10.2% | 17.6% | |
Fair Value Upside | Unlock | −22.7% | 3.0% | Unlock |